Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2026-01-28 @ 1:34 PM
Study NCT ID:
NCT04090567
Status:
RECRUITING
Last Update Posted:
2025-09-18
First Post:
2019-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Breast Carcinoma | View |
| None | Anatomic Stage III Breast Cancer AJCC v8 | View |
| None | Anatomic Stage IIIA Breast Cancer AJCC v8 | View |
| None | Anatomic Stage IIIB Breast Cancer AJCC v8 | View |
| None | Anatomic Stage IIIC Breast Cancer AJCC v8 | View |
| None | Anatomic Stage IV Breast Cancer AJCC v8 | View |
| None | Germline BRCA1 Gene Mutation | View |
| None | Germline BRCA2 Gene Mutation | View |
| None | HER2/Neu Negative | View |
| None | Metastatic Breast Carcinoma | View |
| None | Prognostic Stage III Breast Cancer AJCC v8 | View |
| None | Prognostic Stage IIIA Breast Cancer AJCC v8 | View |
| None | Prognostic Stage IIIB Breast Cancer AJCC v8 | View |
| None | Prognostic Stage IIIC Breast Cancer AJCC v8 | View |
| None | Prognostic Stage IV Breast Cancer AJCC v8 | View |
Keywords: